Curium acquires Eczacıbaşı-Monrol to expand Lu-177 capacity and PET network.

Curium, a nuclear medicine leader, is set to expand its Lu-177 capacity and PET footprint via an agreement to acquire Eczacıbaşı-Monrol. The acquisition will create a leading Lu-177 manufacturer, add 12 PET sites to Curium's network, and incorporate SPECT manufacturing capabilities and logistics infrastructure. This move aims to enhance patient reliability for diagnostic and therapeutic solutions.